DB:5C1A

Stock Analysis Report

Executive Summary

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Esperite's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5C1A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-60.4%

5C1A

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-73.1%

5C1A

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: 5C1A underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 5C1A underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

5C1AIndustryMarket
7 Day-60.4%-4.1%-5.7%
30 Day-66.3%-8.2%-5.7%
90 Day-21.4%-2.0%-3.6%
1 Year-73.1%-73.1%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Esperite's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Esperite undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Esperite is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Esperite has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Esperite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Esperite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Esperite performed over the past 5 years?

23.0%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if 5C1A has high quality earnings.

Growing Profit Margin: Insufficient data to determine if 5C1A's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 5C1A's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare 5C1A's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if 5C1A's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: 5C1A has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Esperite's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if 5C1A's short term assets cover its short term liabilities.

Long Term Liabilities: 5C1A has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 5C1A is debt free.

Reducing Debt: 5C1A had no debt 5 years ago.


Balance Sheet

Inventory Level: Insufficient data to determine if 5C1A has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 5C1A's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 5C1A has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 5C1A has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Esperite's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 5C1A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5C1A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5C1A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5C1A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 5C1A is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5C1A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average board tenure


CEO

Frédéric Amar (55yo)

5.9yrs

Tenure

€510,000

Compensation

Mr. Frédéric A. Amar has been Chief Executive Officer and Executive Director of Esperite N.V. (Formerly Cryo-Save Group N.V.) since March 19, 2014 and served as its Non Executive Director since November 20 ...


CEO Compensation Analysis

Compensation vs Market: Frédéric's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Insufficient data to compare Frédéric's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Frédéric Amar
CEO & Executive Director5.9yrs€510.00kno data
Ronald H. Lorijn
Non-Executive Director9.8yrs€49.00kno data
Vincent M. Borgeot
Non-Executive Director4.7yrs€43.00kno data
Paolo Revoltella
Member of the Scientific Advisory Board0yrsno datano data
Gert-Jan van der Marel
Chairman5.3yrs€58.00kno data

5.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 5C1A's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Esperite N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Esperite N.V.
  • Ticker: 5C1A
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €2.255m
  • Shares outstanding: 52.33m
  • Website: https://www.esperite.com

Number of Employees


Location

  • Esperite N.V.
  • Herengracht 282
  • Amsterdam
  • Noord-Holland
  • 1016 BX
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0OMGLSE (London Stock Exchange)YesOrdinary SharesGBEURNov 2007
5C1ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2007
ESPENXTAM (Euronext Amsterdam)YesOrdinary SharesNLEURNov 2007
ESPABATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURNov 2007

Biography

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company’s products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave’s whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 21:55
End of Day Share Price2020/02/25 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.